Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of AZD0837 versus vitamin K antagonist therapy in atrial fibrillation
2006-005437-38Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atecegatran metoxil in Atrial fibrillation (AFib) (5 arms), sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability outcomes. Started Nov 2006; status: completed.
02
Drugs
atecegatran metoxil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2006-005437-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005437-38.